GA-Imuccor in Brief  (​Nasal Spray)

GA-Immucor is recommended for the treatment of patients with Immunodeficiency disorder.
Preclinical and clinical trials shows, that GA-Immucor has immunocorrective properties - correction and restoration of the immune status of the organism. Plant natural origin medicine GA-Immucor is absolutely harmless and has a high clinical immunotherapeutic efficacy.
GA-Immucor   now pass registration at the Pharmacological Committee of the Ministry of Health and Social Affairs of Georgia.
GA-Immucor has passed preclinical and clinical trials in following organizations:

  • Medical & Biological Scientific Research Centre – Company <<Alexis>>;

  • Research Laboratory of Biomedical Technologies, St. Andrew the First-Called Georgian University of the Patriarchate of Georgia;

  • Clinical and Experimental Research Institute of Tbilisi State Medical University;

  • Institute of Experimental Pathology, Oncology, and Radiobiology at the National Academy of Sciences of Ukraine;

  • Department of Biochemistry of Ukrainian State University;

  • Bukovin State Medical University of Ukraine;

  • Medical Research Institute of Physical Chemistry at the Ministry of Healthcare of Russian Federation;

  • Pharmacological Department of the Medical University of Russian Federation;

  • Research Institute of the Otsuka Pharmaceutical Co., Japan Tokushima Cell Technology Institute, Japan;

  • Fuji Memorial Institute of the Preclinical Research, Bivako/Japan;

  • Tokushima Otsuka Immunology Research Institute, Japan;


Preclinical and clinical trials shows, that GA-Immucor has immunocorrective properties that make a correction of the immune status of the organism and restore the quantitative and functional indicators T and B of immune cellular systems i.e. T-helper cells, T-cytotoxic cells, T-killers (NK-cells), macrophages and granulocytes. It regulates the correlation of T-helper and T-suppressor cells. It also regulates the indicators of immunoglobulin’s, restore the production of cytokines, including the tumor necrosis factor (TNF-a) and interferon’s (INF).
GA-Immucor restores the functional activity of stem haemopoietic cells too, normalizing the content of leukocytes, erythrocytes, neutrophils, thrombocytes, lymphocytes and other blood forming elements. GA-Immucor provides for normalization of the blood biochemical indicators
– total protein, albumin, globulin, urea nitrogen, creatinine, bilirubin,glucose, as well as certain enzymes such as alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), γ-glutamine-transpeptidase (γ-GP) and alkaline phosphatase. The preparation renders a positive influence on the dynamic contents in the bloodstream of carcinoembryonic antigens (CEA), alpha-fetoprotein (AFP), prostate-specific antigen (PSA), as well as the blood contents in mineral compounds of sodium, calcium, potassium.
GA-Immucor is absolutely harmless and has a high clinical immunotherapeutic efficacy for preventive treatment for patients at risk (genetic predisposition coupled with environmental challenges), and those with precancerous lesions; for prophylaxis. It is recommended for persons above 40-50 age, to allow getting rid of senile non-specific diseases, to reduce the risk of cancer, to create the state of the organism in which susceptibility to virus and other infectious diseases are reduced to a minimum.

GA-Immucor is absolutely harmless and has a high clinical immunotherapeutic efficacy for preventive treatment of the patients at risk (genetic predisposition coupled with environmental challenges), and those with precancerous lesions; For prophylaxis, it is recommended for persons above 40-50 age, to allow getting rid of senile non-specific diseases, to reduce the risk of cancer, to create the state of the organism in which susceptibility to virus and other infectious diseases are reduced to a minimum.
 
Autoimmune Diseases
Hemorrhagic vasculitis, glomerulonephritis, rheumatism, arthritis and other deformities
In autoimmune diseases in 90% of cases are completely stopping autoagression. If the disease is short-term and no rough irreversible changes, visible remission lasts up to 5-6 years.

Medical & Biological Scientific - Research Center“ALEXIS” LTD

© Alexis ltd. 2015. All Rights Reserved. The use of the information on this site is subject to the terms of our Legal Notice. This site is published by Alexis ltd, which is solely responsible for its contents. Product names are trademarks of Alexis ltd. This information is intended for use by our customers, patients, and healthcare professionals. Alexis ltd recognizes that the internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside Georgia.